Detalhe da pesquisa
1.
Effects of Serelaxin in Patients with Acute Heart Failure.
N Engl J Med
; 381(8): 716-726, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433919
2.
Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.
J Card Fail
; 23(1): 63-71, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27825893
3.
In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway.
Front Immunol
; 14: 1180833, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37457736
4.
Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against Haemophilus influenzae type b.
Front Immunol
; 13: 1020580, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36578495
5.
Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials.
Circ Heart Fail
; 15(4): e009199, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35184572
6.
Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals.
Front Immunol
; 12: 747594, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34691058
7.
Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals.
Front Immunol
; 12: 732146, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34707606
8.
Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials.
J Am Heart Assoc
; 10(18): e022288, 2021 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34514815
9.
Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial.
Eur J Heart Fail
; 22(4): 726-738, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32141161
10.
Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2.
JACC Heart Fail
; 8(12): 999-1008, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189635
11.
Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins.
Oncogene
; 23(20): 3501-8, 2004 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-15116089
12.
Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells.
Oncogene
; 21(29): 4567-76, 2002 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-12085235
13.
Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial.
Eur J Heart Fail
; 21(12): 1661-1662, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31359535
14.
ErbB receptors: directing key signaling networks throughout life.
Annu Rev Pharmacol Toxicol
; 44: 195-217, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-14744244
15.
The ErbB receptors and their role in cancer progression.
Exp Cell Res
; 284(1): 99-110, 2003 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-12648469
16.
Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells.
EMBO Rep
; 4(2): 166-71, 2003 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-12612606
17.
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
Proc Natl Acad Sci U S A
; 100(15): 8933-8, 2003 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-12853564